AHF Hails HRSA Stance Against J&J’s Illegal Attack on 340B Program

In Featured, News by Ged Kenslea

WASHINGTON (September 27, 2024) – AIDS Healthcare Foundation (AHF) welcomes the strong stand the U.S. Health Resources and Services Administration (HRSA) took today against Johnson & Johnson’s illegal actions that would destroy the 340B Drug Pricing Program.  See HRSA Response to J&J’s September 19, 2024 Letter

J&J’s illegal scheme will deny required 340B discounts to eligible safety net covered entities and instead provide rebates if and when it chooses. J&J’s scheme may or may not reimburse providers at a later date, cheating safety net providers, making every claim subject to dispute and protracted payment.  J&J is violating the law and AHF is pleased that HRSA has swiftly responded.

Drug companies who want the lucrative opportunity to sell their medications to the multi-billion-dollar Medicaid and Medicare drug programs, by law, must offer discounts to eligible nonprofit healthcare providers, such as nonprofit rural hospitals, HIV and black lung disease clinics.  If J&J doesn’t want to comply with the law, HRSA is saying that it will block it from selling its products to the taxpayer supported Medicaid and Medicare drug markets.  J&J can’t unilaterally rewrite healthcare law.

AHF calls on the U.S. Congress to take swift action to explicitly outlaw this blatant illegal action which would blow a hole in the U.S. healthcare safety net.

 

 

 

J&J Retreats from its Scheme to Gut 340B Drug Pricing Program
AHF Webinar Panel Discussion - Airborne Disease on the Rise: Responding to Global Surges Post-COVID-19